DeepMed Research

Akeso

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: $5B

Website

Clinical Trials

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis

Phase 3

Not yet recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: placebo

First Posted Date: 2025-01-10

Last Posted Date: 2025-01-10

Lead Sponsor: Akeso

Target Recruit Count: 198

Registration Number: NCT06767540

Locations: 🇨🇳
The Second Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Chongqing Traditional Chinese Medicine Hospital, Chongqing, Chongqing, China

and more 25 locations

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)

Phase 2

Not yet recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: AK120

First Posted Date: 2025-01-01

Last Posted Date: 2025-01-01

Lead Sponsor: Akeso

Target Recruit Count: 24

Registration Number: NCT06756126

Locations: 🇨🇳
Dongguan People's Hospital, Dongguan, Guangdong, China
🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳
The University of Hong Kong - Shenzhen Hospital, Shenzhen, Guangdong, China

and more 3 locations

A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Cancer

Interventions: Drug: AK138D1

First Posted Date: 2024-12-12

Last Posted Date: 2025-03-06

Lead Sponsor: Akeso

Target Recruit Count: 100

Registration Number: NCT06730386

Locations: 🇦🇺
Blacktown Hospital-Blacktwon Cancer and Haematology Centre, Blacktown, New South Wales, Australia
🇦🇺
Macquarie University, North Ryde, New South Wales, Australia
🇦🇺
ICON Cancer Centre South Brisbane, South Brisbane, Queensland, Australia

and more 1 locations

A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Phase 2

Recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)

First Posted Date: 2024-11-22

Last Posted Date: 2024-11-22

Lead Sponsor: Akeso

Target Recruit Count: 450

Registration Number: NCT06700499

Locations: 🇨🇳
Changde First People's Hospital, Changde, Hunan, China
🇨🇳
XiangYa Hospital CentralSouth University, Changsha, Hunan, China
🇨🇳
Yueyang Central Hospital, Yueyang, Hunan, China

and more 47 locations

AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Malignant Tumors

Interventions: Drug: AK137

First Posted Date: 2024-11-15

Last Posted Date: 2024-11-15

Lead Sponsor: Akeso

Target Recruit Count: 87

Registration Number: NCT06691360

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

Phase 2

Recruiting

Conditions: Platinum-sensitive Ovarian Cancer

Interventions: Drug: AK112 low dose
Drug: Chemotherapy
Drug: Olaparib
Drug: AK112 high dose

First Posted Date: 2024-11-13

Last Posted Date: 2025-04-16

Lead Sponsor: Akeso

Target Recruit Count: 150

Registration Number: NCT06686030

Locations: 🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science And Technology, Wuhan, China

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Phase 1

Recruiting

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Drug: AK112, nab-paclitaxel, gemcitabine
Drug: nab-paclitaxel, gemcitabine
Drug: AK112, Cadonilimab, nab-paclitaxel, gemcitabine

First Posted Date: 2024-10-17

Last Posted Date: 2025-01-23

Lead Sponsor: Akeso

Target Recruit Count: 110

Registration Number: NCT06646055

Locations: 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology., Wuhan, Hubei, China

A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects

Phase 1

Not yet recruiting

Conditions: Healthy Subjects (HS)

Interventions: Drug: Ebronucimab

First Posted Date: 2024-10-15

Last Posted Date: 2024-10-15

Lead Sponsor: Akeso

Target Recruit Count: 180

Registration Number: NCT06641388

Locations: 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China

A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Classic Hodgkin Lymphoma

Interventions: Drug: AK129
Drug: AK117

First Posted Date: 2024-10-15

Last Posted Date: 2025-02-11

Lead Sponsor: Akeso

Target Recruit Count: 280

Registration Number: NCT06642792

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Phase 3

Recruiting

Conditions: NSCLC (Non-small Cell Lung Cancer)

Interventions: Drug: Cadonilimab (AK104)
Drug: Sugemalimab

First Posted Date: 2024-09-27

Last Posted Date: 2025-03-12

Lead Sponsor: Akeso

Target Recruit Count: 560

Registration Number: NCT06617416

Locations: 🇨🇳
Cancer Hospital of Shandong First Medical University, Jinan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy